Courier service EMS
Other transport services
Air India Post International
Payment in the bank on the invoice
WestrUnion
MoneyGram
Pomalid 2mg is an antineoplastic drug, which is used by the patients who are having a valid prescription and under the supervision of medical oncologist.
Pomalid 2mg affects the immune system. It encourages immune responses to help reduce tumor growth.
The primary indication of Pomalid 2mg is used in the treatment of Multiple Myeloma condition.
In this condition, Pomalid 2mg is used by interaction with dexamethasone.
Pomalid 2mg capsules are indicated in Patients already got therapy with two medications such as proteasome inhibitor & Lenalidomide. followed within 60 days in patients who are concluded the last treatment.
Pomalid tablets are available in the strength of 1mg, 2mg and 4mg
Pomalidomide is a thalidomide analogue; it is used in combination with dexamethasone
The recommended dose of Pomalid tablets in multiple myeloma condition, 4mg should be taken orally as a single dose on days 1-21 of repeated 28 days cycles until disease advancement
Pomalid given in combination with low dose of dexamethasone
Dexamethasone should be given orally only in days of 1, 8, 15 and 22 of each 28 days
>75 years: 20mg/day
≤75 years: 40mg/day
Dose modification:
Pomalidomide therapy should be discontinue, if toxicities occur after dose reduction to 1mg (in case of neutropenia and thrombocytopenia)
<18 years: the safety and efficacy of the Pomalid tablets has been established
Pomalid tablets should be taken with water; it should not chew, break or open
Pomalid should be taken with or without food
Pomalid combined with CYP1A2 substrates causes increasing the plasma concentration of Pomalidomide and leads to elevate the risk of Pomalidomide.
No specific antidote is used for over dosage of Pomalidomide. Patient should be provided with general supportive measures. Monitor the signs & symptoms
Pomalid 2mg combination with CYP1A2 drugs causes increased concentration of Pomalidomide.
Overcome this problem by decreasing the dose of Pomalid 2mg during this combination therapy.
Thalidomide associate which evoke immunomodulatory and antineoplastic activity; it prohibits replication and induced apoptosis of hematopoietic tumor cells
Additionally, it increases T-cell and natural killer cell-mediated immunity and restrain production of TNF-alpha and interleukin-6; down-modulates cell surface adhesion molecules contain in leukocyte migration.
Anticancer activity may be due to inhibition of angiogenesis
Absorption: The peak plasma concentration time of Pomalidomide is arrives between 2 to 3 hours.
Distribution: Pomalidomide is bounded to human plasma protein by range of 12% & 44%.
Metabolism: The metabolism of Pomalidomide is appears via hepatically mediated through CYP1A2, CYP3A4.
Elimination: The Pomalidomide clearance value is 7 to 10L/hr.
Doses are excreted via urine 73% & feces 15% respectively.
Doses are excreted as in unchanged form through urine 2% & feces 8%.
The half-life period of Pomalidomide is 9.5 hours
Pomalid 2mg is contraindicated to;
Pregnancy
Lactation
Hypersensitivity reactions produced due to patients are contraindicated to the component of Pomalid 2mg.
Pregnancy category of Pomalid 2mg is X. Pomalid 2mg usage during pregnancy period, leads to fetal harm and causes death.
Breast feeding should not be recommended.
The Pomalid 2mg capsules container should be stored at 20oC to 25oC
Protect the container from moisture, heat, & light.
If missed dose occurs, consult with physician & follow the regular dosing schedule. Or skip the missed dose and follow the routine timing. Otherwise Missed dose leads to over dosage condition.